根治性肝切除联合索拉非尼治疗肝细胞癌的研究进展

Adjuvant sorafenib after radical liver resection for the treatment of hepatocellular carcinoma:Recent research advances

根治性肝切除仍然是肝细胞癌(hepatocellularcarcinoma,HCC)的主要治疗手段,但术后转移复发导致肝切除的疗效进入瓶颈期.探索术后复发的治疗措施是有效延长患者生存时间的重要课题.目前,以经皮肝动脉化疗栓塞为代表的多种治疗措施已在临床广泛开展,但尚缺乏大规模、多中心随机对照临床试验的循证医学证据.分子靶向药物索拉非尼的出现为改善HCC预后开辟了新局面,对于已接受过根治性肝切除治疗的HCC患者,索拉非尼可能是一种有效的辅助治疗方法,值得深入探索.

Radical liver resection is still the major treatment for hepatocellular carcinoma（HCC） in recent years.However,postoperative recurrence and metastasis are major obstacles that lead to poor therapeutic benefits.Treatments to prevent recurrence are important for effectively prolonging the survival of HCC patients.Currently,various treatment options,such as transcatheter hepatic arterial chemoembolization,have been comprehensively assessed in clinical practice;however,evidence from large multicenter,randomized controlled trials is still lacking.The emergence of sorafenib,a molecular targeted drug,has opened a new avenue for improving the prognosis of HCC prognosis.Sorafenib might be an effective adjuvant treatment for HCC patients who received curative liver resection. 更多